Home › Compare › HOFJF vs ABBV
HOFJF yields 1.45% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, HOFJF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HOFJF + ABBV for your $10,000?
House Foods Group Inc. engages in the manufacture, sale, import, and export of spices, seasonings, processed foods, and commercial use food products in Japan and internationally. It operates through Spice/Seasoning/Processed Food Business, Health Food Business, Restaurant Business, International Food Business, and Other Food Related Business segments. The company offers curry, stew, starch, processed meat, retort pouched food products, etc.; condiments, such as curry roux products; soy-bean products, prepared dishes, baked breads, dessert products, and beverages; health food products through mail-order; and frozen vegetables, mustard essential oils, processed foods, etc. It also conducts agricultural management; processes and sells agricultural products; provides safety and sanitation analysis for food products; and operates and transport and warehouses. In addition, the company is involved in the restaurant operations guidance and trading services; and marketing of vegetables. It operates 1,259 restaurants in Japan and 202 restaurants internationally under the Ichibanya name. The company was formerly known as House Foods Corp and changed its name to House Foods Group Inc. in 2013. House Foods Group Inc. was founded in 1913 and is headquartered in Tokyo, Japan.
Full HOFJF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.